Interv Akut Kardiol. 2019;18(3):170-171

The COMMANDER-HF trial

Jiří Vítovec
I. interní kardioangiologická klinika FN u sv. Anny a LF MU, Brno

The COMMANDER-HF trial studied the effect of administering a low dose of rivaroxaban of 2.5 mg twice daily in patients with
heart failure who had a sinus rhythm. The study showed that administration of rivaroxaban did not affect the primary composite
endpoint (death from any cause, myocardial infarction, or stroke) compared to placebo. Additionally, no higher rate of major
bleeding was observed. A post-hoc analysis showed a significantly lower incidence of ischaemic stroke with rivaroxaban.

Keywords: heart failure, rivaroxaban, sinus rhythm, stroke

Published: November 1, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J. The COMMANDER-HF trial. Interv Akut Kardiol. 2019;18(3):170-171.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Zannad F, Greenberg B, Cleland JGF, et al. Rationale and design of a randomized, double-blind, event-driven, multicentre study comparing the efficacy and safety of oral rivaroxaban with placebo for reducing the risk of death, myocardial infarction or stroke in subjects with heart failure and significant coronary artery disease following an exacerbation of heart failure: the COMMANDER HF trial. Eur J Heart Fail 2015; 17: 735-742. Go to original source... Go to PubMed...
    2. Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. N Engl J Med 2018; 379: 1332-1342. Go to original source...
    3. Vaduganathan M. Effect of rivaroxaban on stroke or transient ischemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. 2019 Heart Failure Congress Atheny; abstract 648.

    Return to the content


    Interventional Cardiology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.